1-cyclohexylthymine
1-Cyclohexylthymine is a modified nucleoside, specifically a **thymine analog**. It's important to understand that thymine is one of the four nitrogenous bases found in DNA, and thymine analogs are synthetic molecules that share structural similarities with thymine, leading to interesting interactions with DNA and other biological systems.
Here's what makes 1-cyclohexylthymine significant in research:
**1. Antiviral Properties:**
* 1-Cyclohexylthymine has shown potent antiviral activity against viruses like herpes simplex virus (HSV), which causes cold sores and genital herpes. This antiviral activity stems from its ability to inhibit viral DNA polymerase, an enzyme essential for viral replication.
**2. Potential as an Anticancer Agent:**
* Due to its structural resemblance to thymine, 1-Cyclohexylthymine can be incorporated into DNA, potentially disrupting its structure and function. This property makes it a promising candidate for anticancer therapy, as it could interfere with the growth and proliferation of cancer cells.
**3. Investigating DNA Structure and Function:**
* Researchers use modified nucleosides like 1-Cyclohexylthymine to study DNA structure and how it interacts with various proteins. By introducing these analogs into DNA, scientists can gain insights into the complex processes of DNA replication, repair, and transcription.
**4. Building Blocks for Novel Therapeutics:**
* 1-Cyclohexylthymine and similar analogs serve as starting points for designing novel antiviral, anticancer, and other therapeutic agents. By modifying their structure, researchers can fine-tune their properties to achieve specific therapeutic goals.
**Important Note:** 1-Cyclohexylthymine is still in the research stage and has not yet been approved for clinical use. Further research is needed to fully understand its potential benefits and safety profile.
In summary, 1-Cyclohexylthymine is a valuable tool for researchers in various fields, offering potential benefits for antiviral and anticancer treatments, as well as furthering our understanding of DNA structure and function.
Cross-References
ID Source | ID |
---|---|
PubMed CID | 96032 |
MeSH ID | M0057734 |
Synonyms (14)
Synonym |
---|
nsc-49061 |
21031-74-3 |
nsc49061 |
mls002667232 , |
1-cyclohexylthymine |
smr001557001 |
HMS3089M19 |
2,4(1h,3h)-pyrimidinedione, 1-cyclohexyl-5-methyl- |
unii-f71ly04j3w |
nsc 49061 |
f71ly04j3w , |
DTXSID90175236 |
1-cyclohexyl-5-methyl-2,4(1h,3h)-pyrimidinedione |
thymine, 1-cyclohexyl- |
Bioassays (11)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |